

*EID cannot ensure accessibility for supplementary materials supplied by authors.*

*Readers who have difficulty accessing supplementary content should contact the authors for assistance.*

# Fort Sherman Virus Infection in Human, Peru, 2020

## Appendix

### Materials and methods

#### Sampling

Serum samples were collected for the SARS-CoV-2 seroprevalence Study in Peru in collaboration with the Ministry of Health. Procedures were performed according to the approval of the Institutional Bioethics Committee VÍA LIBRE under protocol number 6528.

#### Molecular detection

For the screening testing for orthobunyavirus, a previously published broad reactive RT-PCR was used (1). The amplicon of the positive sample was sent for Sanger sequencing and then analyzed by BLASTN for virus identification. The FSV positive serum was then quantified by a real-time RT-PCR based on the viral polymerase gene using the primers FSHV-rtF (5'-TGTTGGTGATTGTGCATATATTGG), FSHV-rtR (5'-GGCGGACAACCATGTTAACACT) and the probe FSHV-rtP (5'-ATCTAGCCAGTAGGTTATCTGCCACGCAGC), as previously published (2).

Sera were screened for the presence of dengue virus (DENV) using a commercial real-time RT-PCR (TIB Molbiol). Additional screening for other flaviviruses and alphaviruses was performed by broadly reactive nested RT-PCR, also using previously published tests (3,4).

#### Viral Isolation attempts

For virus isolation, monolayers of  $1.6 \times 10^5$  cells per well were seeded in 12 well plates. The RT-PCR-positive serum was diluted at 1:10 and 1:100, inoculated into Vero E6, Vero FM, BHK and C6/36 cell lines, and incubated for 1 hour, as described previously (2). Cells were observed daily for 7 days for the presence of a cytopathic effect (CPE). After 7

days, cells were passaged, monitored daily and tested by real-time RT-PCR. Blind passages were repeated two times.

### **Evolutionary analysis**

Maximum likelihood (ML) phylogenetic trees were performed using translated amino acid sequences of all three coding sequences using MEGA X (5) and 1,000 bootstrap replicates, a WAG amino acid substitution model, and complete deletion of all positions containing gaps in the alignment. Amino acid and nucleotide pairwise sequence distances were calculated in MEGA X using a pairwise deletion of all positions containing gaps in the alignment. Additional information on the selected orthobunyaviruses reference sequences used to build phylogenetic trees and for the sequence distance comparisons is detailed in Appendix Table 1.

### **Sequencing**

Primers for each genomic segment are available in Appendix Table 2.

### **References**

1. Lambert AJ, Lanciotti RS. Consensus amplification and novel multiplex sequencing method for S segment species identification of 47 viruses of the Orthobunyavirus, Phlebovirus, and Nairovirus genera of the family Bunyaviridae. *J Clin Microbiol*. 2009;47:2398–404. [PubMed](#) <https://doi.org/10.1128/JCM.00182-09>
2. de Oliveira Filho EF, Carneiro IO, Ribas JRL, Fischer C, Marklewitz M, Junglen S, et al. Identification of animal hosts of Fort Sherman virus, a New World zoonotic orthobunyavirus. *Transbound Emerg Dis*. 2020;67:1433–41. [PubMed](#) <https://doi.org/10.1111/tbed.13499>
3. Moureau G, Temmam S, Gonzalez JP, Charrel RN, Grard G, de Lamballerie X. A real-time RT-PCR method for the universal detection and identification of flaviviruses. *Vector Borne Zoonotic Dis*. 2007;7:467–77. [PubMed](#) <https://doi.org/10.1089/vbz.2007.0206>
4. Grywna K, Kupfer B, Panning M, Drexler JF, Emmerich P, Drosten C, et al. Detection of all species of the genus Alphavirus by reverse transcription-PCR with diagnostic sensitivity. *J Clin Microbiol*. 2010;48:3386–7. [PubMed](#) <https://doi.org/10.1128/JCM.00317-10>
5. Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: Molecular Evolutionary Genetics Analysis across computing platforms. *Mol Biol Evol*. 2018;35:1547–9. [PubMed](#) <https://doi.org/10.1093/molbev/msy096>

**Appendix Table 1.** Reference sequences used for evolutionary inferences\*

Virus	Strain	L	M	S	Host detected	Country	Year†
Anadyr	LEIV-13128Kam	KT313717.1	KT313718.1	KT313719.1	<i>Aedes</i> sp.	Russia	1986
Batai	NM/12	KJ187038.1	KJ187039.1	KJ187040.1	Cattle	People's Republic of China	2012
Bunyamwera		X14383.1	M11852.1	D00353.1			1991‡
CVV Colombia	CoAr 3363	KX100108.1	KX100107.1	KX100106.1	<i>Aedes scapularis</i>	Colombia	1964
CVV Mexico	61D240	MH484342.1	MH484343.1	MH484344.1	<i>Mansonia titillans</i>	Mexico	1961
CVV USA	R132738d	OL555724.1	OL555725.1	OL555726.1	<i>Homo sapiens</i>	USA	2021
FSV (1965)	CbaAr426	KX100111.1	KX100110.1	KX100109.1	<i>Ochlerotatus albifasciatus</i>	Argentina	1965
FSV (1982)	AG83-1746	KX100114.1	KX100113.1	KX100112.1	<i>Psorophora varinervis</i>	Argentina	1982
FSV Argentina	SFCrEq231	KP063892.1	KP063893.1	KP063894.1	Horse	Argentina	2013
FSV Brazil	Barreiras	MN379835.1	N379834.1	MN379833.1	Horse	Brazil	2018
FSV Panama	86MSP18	NC_043617.1	NC_043615.1	NC_043616.1	<i>Homo sapiens</i>	Panama	1985
FSV Peru					<i>Homo sapiens</i>	Peru	2020
Ilesha	R5964	KF234075.1	KF234074.1	KF234073.1	<i>Homo sapiens</i>		1968
Kairi	BeAr8226	KR260738.1	KR260739.1	KR260740.1	<i>Ochlerotatus scapularis</i>	Brazil	1957
Lokern	FMS 4332	MG828823.1	MG820264.1	MG696865.2	<i>Culex tarsalis</i>	USA	1962
Maguari	OBS 6657	ARI46638	ARI46637.1	ARI46635.1	<i>Homo sapiens</i>	Peru	1998
Main Drain	72V2567	MH484306.1	MH484307.1	MH484308.1	<i>Aedes vexans</i>	USA	1972
Northway	0234	AVX27622	ABV68911.1	AXM42966.1	<i>Aedes</i> sp.	USA	1971
Playas	75V5758	ARI46654	ARI46653.1	ARI46651.1	<i>Aedeomyia taeniorhynchus</i>	Ecuador	1975
Potosi	89-3380	AXP32050	AXP32051.1	AXP32052.1	<i>Aedes albopictus</i>	USA	1961
Tensaw	TSV-FL06	ACV95628	ACV95623.1	ACV95624.1	<i>Anopheles crucians</i>	USA	2006

\*CVV, Cache Valley virus; FSV, Fort Sherman virus.

†Isolation or detection year.

‡The sequence release date was used when information was not available.

**Appendix Table 2.** Primers used for amplification of complete coding sequence of FSV genomic segments\*

Oligo name	Oligo sequence	Orientation
S segment		
FSV S F1	CGAGCGGTAGTAGTGTACTC	forward
FSV S F2	AGTAGTGTACTCCACACTAATAAC	forward
FSV S R1	AGTAGTGTGCTCCACCTAAACT	reverse
FSV S R3	GGATAGAATTGAAATGTTCTTAAGAA	reverse
FSV S R2	TTCAGATCTGGGAAGAACATGAG	reverse
FSV S F3	CTTGGCTGAAAAAAATGGAATTACA	forward
FSV S R4	TTTCAGATCCTGGGAAGAACATGAG	reverse
FSV S F4	CTTTGGCTGAAAAAAATGGAATTAC	reverse
M segment		
FSV M F14	CAGATGTAAGACTTGGTTATGTAG	forward
FSV M F1	GTAAGTAGTGTACTACCGATACAAT	forward
FSV M F2	CTTAGTCTAAATGACAAAGACATACA	forward
FSV M F3	AGATCTTAGCTAAATGACAAAGACA	forward
FSV M F4	ATTGATGAAAAGGACAGCAGATGTA	forward
FSV M F5	GTTATCTACTGATGCCAATTTCATG	forward
FSV M F6	AAATAACAAGCATACTAGCAAGAAGA	forward
FSV M F7	ACAAGCATACTAGCAAGAAGAACATG	forward
FSV M F8	TTAAGGCAATCAGAGCCCAGAAA	forward
FSV M F9	GGAGTCTGGAAATTGGACAGT	forward
FSV M F10	GGAGTCTGGAAATTGGACAGTA	forward
FSV M F11	GGCAGATAAAGGCCTTTGTACA	forward
FSV M F12	GAATCAGCATACATCTGTCTAGTA	forward
FSV M F13	CCAGGCAATAATTACTGCACTGA	forward
FSV M R1	CCTCCTCTTATCTATGGTTATAGT	reverse
FSV M R2	GCCTCCTCTTATCTATGGTTATA	reverse
FSV M R3	CACTTTTGAGCTCTTGTGTA	reverse
FSV M R4	GCACTTTGAGCTCTTGTGTA	reverse
FSV M R5	TCACCGTTACTTTATGCCTCTT	reverse
FSV M R6	TCACCGTTACTTTATGCCTCTT	reverse
FSV M R7	GGTTGAAACTCGTGTAAATCACAC	reverse
FSV M R8	GCTCAATTCACTGGTTATTATGTATG	reverse
FSV M R9	CTCCTATTCTGGCTCAATTCACTG	reverse

Oligo name	Oligo sequence	Orientation
FSV M R10	GAAGTAGTACAATCCACTATCACAT	reverse
FSV M R11	GGAAATTGCTTTGGTTGGACAT	reverse
FSV M R12	GGAAATTGCTTTGGTTGGACATT	reverse
FSV M R13	CTGGAGCTCATCTCATCTGTT	reverse
FSV M R14	ACTGGAGCTCATCTCATCTGTT	reverse
FSV M R15	TAGCTTCAAAACACGATGGACAT	reverse
FSV M R16	GCAGGAGTAGCTTCAAAACAC	reverse
FSV M R17	TGTGCTACCGATATCAAAAACAG	reverse
M5'Rev	CCT GTC GACAGTAGTGTGCT	reverse
L Segment		
FSV L F01	TGTAGTAGTGACTCCTATATAAAGA	forward
FSV L F02	TCCCTGGATTATAAAAGTGTCAAGTTG	forward
FSV L F03	ATGGGATCTATGCCACCTAGAT	forward
FSV L F04	GTAGAACCTCAACATGGACAGA	forward
FSV L F05	CAGAACCTCAACATGGACAGAT	forward
FSV L F06	GCTTCTTGTCTCAGAATAATACACT	forward
FSV L F07	AGATGCCAGCGAATTGTCTCTT	forward
FSV L F08	AAATGATGAAAGGAATCTGGATTCTA	forward
FSV L F09	AAATGATGAAAGGAATCTGGATTCT	forward
FSV L F10	AGTATAGACTATCGAACCCATTGTT	forward
FSV L F11	AAGTATAGATTATCGAACCCATTGTT	forward
FSV L F12	AGGAAAGGTGCAAGTTAAACTGAT	forward
FSV L F13	GGAAAGGTGCAAGTTAAACTGAT	forward
FSV L F14	CTACTGTCATGTGCTTGATCAA	forward
FSV L F15	CCTTCAGAATGATCTAACTAGA	forward
FSV L F16	TCTTACTACCAAGTGTGGTGATT	forward
FSV L F17	CACAGTGCCAGTGGCTAACAA	forward
FSV L F18	ACACAGTGCAGTGGCTAACAA	forward
FSV L F19	TGAGCTCACTAGTAGAAATCAGATAT	forward
FSV L F20	CAAGCATTGACAGGCACAGAA	forward
FSV L F21	TGAGGTGATAGATAACTTCCAGTAT	forward
FSV L F22	GTGCTTGACGAAAAATATAACTACTA	forward
FSV L F23	GTGCTTGACGAAAAATATAACTACTA	forward
FSV L F24	AACACAAGAATTGCTGTCAGTCAA	forward
FSV L F25	ACACAAGAATTGCTGTCAGTCAA	forward
FSV L F26	CTAGTGACAAATGAATGGCTTCT	forward
FSV L R01	CCATAACAGGCAAATTAAATGAAGTA	reverse
FSV L R02	TCCATAACAGGCAAATTAAATGAAGT	reverse
FSV L R03	ACCTTCAGCTGAGTAAGCACT	reverse
FSV L R04	GAECTATTCCACCTTCAGCTGA	reverse
FSV L R05	CATAGGTTTCATATTGGCCAACAT	reverse
FSV L R06	CATATTGGCCAACATTACCATCTA	reverse
FSV L R07	CTTCAGATGCTCCTTATTGTGA	reverse
FSV L R08	GTTTAGCACATCCATAAGGGATACT	reverse
FSV L R09	TTTAGCACATCCATAAGGGATACT	reverse
FSV L R10	TAGCATTGAAATAAAAGGGTAGATAGA	reverse
FSV L R11	AGCATTGAAATAAAAGGGTAGATAGA	reverse
FSV L R12	GCTGCCAAATCTTCATAATTACAGT	reverse
FSV L R13	CACATTATAACGTATTTCTCTCTG	reverse
FSV L R14	AGCACAACATGGACATAACTAGA	reverse
FSV L R15	ATACTTTGCTGCGTGGCAGAT	reverse
FSV L R16	ATACTTTGCTGCGTGGCAGATA	reverse
FSV L R17	CTGTGTCTAGAGTTAAGTATCTAAGT	reverse
FSV L R18	TCTGCACAAACCTCTGTGTCTA	reverse
FSV L R19	CTGATAAGCCTGCGGGAAAGT	reverse
FSV L R20	TACTTGACCTTGTGTTCTGTTGA	reverse
FSV L R21	ACTTGACCTTGTGTTCTGTTGA	reverse
FSV L R22	CTATTTAAATCTGCCCTGGGTTAGA	reverse
FSV L R23	TCTGGGTTAGAGCTTGCATTCT	reverse
FSV L R24	ATGTTCGGTTAGAAACCTGATA	reverse
FSV L R25	TATGTTCGGTTAGAAACCTGATA	reverse
FSV L R26	GTGTCCCTCATACCATTACATGA	reverse
FSV L R27	GCTGATGGCAAAGAGAACATGT	reverse
FSV L R28	GTGTGCTCCTATATAAAGAAATTGAT	reverse
FSV L R29	TGAGTAGTGTGCTCCTATATAAAGA	reverse

\*FSV, Fort Sherman virus.


**Appendix Table 3.** Monthly detection ration of Dengue virus in department of Lambayeque, Peru, 2020.

Month	Positives	Total	Frequency
January	4	14	28.6%
February	106	154	68.8%
March	120	194	61.9%
April	114	122	93.4%
May	24	31	77.4%
June	4	6	66.7%
July	18	27	66.7%
August	3	7	42.9%
September	2	2	100.0%
October	5	6	83.3%
November	4	14	28.6%
December	6	6	100.0%
Total	410	583	70.3%

**Appendix Table 4.** Evolutionary divergence between Fort Sherman virus from Peru and related orthobunyaviruses\*

Genomic segments	Human-derived FSV		Horse-derived FSV		CVV		Potosi		Tensaw		Maguari		Northway		Playas	
	N	A	N	A	N	A	N	A	N	A	N	A	N	A	N	A
L	2.0	0.8	5.0	1.9	23.4	12.4	23.7	12.5	21.7	9.4	21.9	10.0	21.2	10.3	21.9	10.4
M	2.3	1.5	24.6	17.3	9.0	3.9	38.3	44.0	26.7	20.6	24.7	14.9	24.3	15.7	25.1	14.6
S	1.0	0.0	3.0	0.0	12.8	3.9	11.8	4.3	11.4	3.4	10.1	4.3	11.6	1.7	15.5	4.3

\*Evolutionary analyses were performed using MEGA10 (Appendix, <https://wwwnc.cdc.gov/EID/article/30/10/24-0124-App1.pdf>). N, indicates percent nucleotide sequence divergence of coding sequence; A indicates percent divergence of translated amino acid sequences. CVV, Cache Valley virus; FSV, Fort Sherman virus.



**Appendix Figure.** Detection rate of dengue virus by real-time RT-PCR among febrile patients in the Lambayeque department, Peru, in 2020. The red asterisk indicates the month a patient tested positive for FSV. The total number of sera tested per month is given in brackets.